CA-DENODO
2.9.2020 09:02:09 CEST | Business Wire | Press release
Denodo , the leader in data virtualization, today announced increased adoption of its Coronavirus Data Portal (CDP), an open, cooperative effort that utilizes data virtualization to unify critical datasets originally exposed in different formats from multiple sources and countries. Originally developed in March during early onset of the pandemic, Denodo has combined and unified COVID-19 related intelligence and made it available to data consumers such as data scientists, analysts, and researchers who are leveraging the information to find solutions to this global disease. For more information, and to participate in the effort, visit https://www.coronavirusdataportal.com .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005272/en/
“In an effort to measure and monitor the health of our employees, we needed to create a way for them to tell us about their own health and to provide the clinical teams and leadership with details on who is healthy and who is not before coming to work,” said Mahendra Parasmal, Sr. Information Architect at Spectrum Health . “Denodo provides us with the ability to connect self-purported health data provided by employees via an online survey with employee demographics, employee hierarchy, badge system & Active Directory data virtually. This delivers wellness information in near real-time without having to Extract, Transform & Load the data physically from source systems or run batch incremental loads. As a result, we have been able to speed up our overall build time by at least 3x and deliver the end result in weeks instead of months.”
Free of charge to participants, the Coronavirus Data Portal enables organizations and institutions to share their individual data sets that Denodo integrates and offers to the broader community for consumption via the data platform. It also allows members to integrate and curate these data sets so they can augment their own COVID-19 initiatives. As of today, there are 64 sources, 220 datasets, and 441 views offered on CDP.
“I can personally attest to how our company was able to leverage Denodo’s Coronavirus Data Portal having developed a COVID-19 virtual hub that provides reports based on data science and pmOne Share ,” said Dr. Norman Bernhardt, Head of Digital Solutions R&D, pmOne . “pmOne Share Cockpit aggregates existing and established reporting solutions and provides advanced filtering capabilities, which data scientists can use to develop algorithms to analyze global news flows, the results of which are displayed in a dashboard.”
More specifically, Denodo’s CDP is being used to:
- Search the Curated Datasets: Coronavirus Data Portal offers a catalog of the curated data sets - both uploaded and curated by Denodo data stewards and those contributed by users of the data portal. This allows users to search the available data sets and find the data relevant to them such as details about the spread of the disease, school closures, financial impact, etc. It also enables them to drill deeper to view details about a particular data set and its relationship with other ones.
- Enhance Dashboard BI Tools with Integrated Data Portal: CDP supports BI tools such as Power BI, Tableau and others so participants can connect to the data portal and generate smart visualizations. Users can use these tools to easily create new customized reports of the integrated data.
- Extend Data integration Using API Service/Downloadable CSV Datasets: Lets users further integrate their application with the Coronavirus Data Platform, utilizing it as an API service layer. This enables users to access the curated data sets in a variety of views and is an option that is growing significantly as more and more multi-faceted data is added from across the globe.
- Contribute to the Initiative: The Coronavirus Data Portal is an open platform, which permits users to contribute their own data sets to the initiative. It suggests data sources that should be added to the Data Portal and Denodo’s data steward team will review the data and usage permissions to determine if it’s appropriate to be uploaded. Alternatively, they can create new data sets by combining the Coronavirus Data Portal data with their own data and share this new data set with other Data Portal users.
“While our data stewards and data engineers have been working behind the scenes to add more data sets to the Coronavirus Data Portal, we have also been getting some great suggestions from the user community. Based on suggestions, we’ve added COVID-19 forecast data, real-time information about how many are infected and where, school closures, global news as they are published, and much more,” said Angel Viña, CEO and Founder at Denodo. “Contributing data sets - either through suggestions or by creating derived data sets - will continue the growth of the Coronavirus Data Portal and enhance the value that fellow users are getting from using the data. This continued growth will provide more varied and richer data for all of us to use and share in our efforts to combat this deadly pandemic.”
Please Tweet: News: #datavirtulization provider @denodo offers complimentary #coronavirus data portal to unify #datasets and information to fight #COVID19
About Denodo
Denodo is the leader in data virtualization providing agile, high performance data integration, data abstraction, and real-time data services across the broadest range of enterprise, cloud, big data, and unstructured data sources at half the cost of traditional approaches. Denodo’s customers across every major industry have gained significant business agility and ROI by enabling faster and easier access to unified business information for agile BI, big data analytics, Web, cloud integration, single-view applications, and enterprise data services. Denodo is well-funded, profitable, and privately held. For more information, visit http://www.denodo.com or call +1 877 556 2531 / +44 (0) 20 7869 8053.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005272/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
